Learn more

FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE «NATSIONALNYI ISSLEDOVATELSKII TSENTR EPIDEMIOLO

Overview
  • Total Patents
    11
  • GoodIP Patent Rank
    152,638
About

FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE «NATSIONALNYI ISSLEDOVATELSKII TSENTR EPIDEMIOLO has a total of 11 patent applications. Its first patent ever was published in 2018. It filed its patents most often in Russian Federation. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are TAIPEI VETERAN GENERAL HOSPITAL, RUBIUS THERAPEUTICS INC and BIONOR IMMUNO AS.

Patent filings in countries

World map showing FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE «NATSIONALNYI ISSLEDOVATELSKII TSENTR EPIDEMIOLOs patent filings in countries
# Country Total Patents
#1 Russian Federation 11

Patent filings per year

Chart showing FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE «NATSIONALNYI ISSLEDOVATELSKII TSENTR EPIDEMIOLOs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Gintsburg Aleksandr Leonidovich 11
#2 Lubenets Nadezhda Leonidovna 5
#3 Logunov Denis Iurevich 5
#4 Dzharullaeva Alina Shakhmirovna 4
#5 Vasina Daria Vladimirovna 4
#6 Tukhvatulin Amir Ildarovich 4
#7 Gushchin Vladimir Alekseevich 4
#8 Zubkova Olga Vadimovna 4
#9 Tukhvatulina Natalia Mikhailovna 4
#10 Tkachuk Artem Petrovich 4

Latest patents

Publication Filing date Title
RU2744444C1 Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination (versions)
RU2744442C1 Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination in people over 60 and/or with chronic diseases (versions)
RU2743962C1 Agent for induction of specific immunity against severe acute respiratory syndrome coronavirus (sars-cov-2) in lyophilized form (versions)
RU2745307C1 METHOD FOR PURIFICATION OF RECOMBINANT ADENOVIRUS 26 SEROTYPE (Ad26)
RU2743927C1 SOLID DISPERSION of 4- (3-ETHOXY-4-HYDROXIBENZIL) -5-OXO-5,6-DIHYDRO-4H- [1,3,4] -THIADIAZINE-2- (2,4-DIFLUOROPHENYL) -CARBOXAMIDE FOR PRODUCING PHARMACEUTICAL FORMULATION AND METHOD OF TREATMENT OF CHRONIC INFECTIOUS DISEASES
RU2737087C1 Pharmaceutical composition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4h-[1,3,4]-thiadiazin-2-(2,4-difluorophenyl) carboxamide in crystalline form , and use thereof as antibacterial agent for treating acute, recurrent and chronic infections
RU2730614C1 Antibacterial composition (embodiments) and use of protein as antimicrobial agent directed against bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi and staphylococcus haemolyticus (embodiments)
RU2730613C1 Antibacterial composition (embodiments) and use of protein as antimicrobial agent directed against bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi and staphylococcus haemolyticus (embodiments)
RU2730615C1 Antibacterial composition (embodiments) and use of protein as antimicrobial agent directed against gram-negative bacteria: pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae and salmonella typhi (embodiments)
RU2726484C1 Diagnostic technique for rickettsial diseases group of spotted fever, immunoassay diagnostic test system for implementation thereof
RU2742580C2 Pharmaceutical composition based on plga for the induction of the effective mucosal immune response